Condition
PSMA PET
Total Trials
5
Recruiting
4
Active
5
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 3 (2)
Trial Status
Recruiting4
Active Not Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07553754Recruiting
Plasma Exosomal RNA Signature for Prostate Cancer Bone Metastasis
NCT07553780Recruiting
Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate Cancer
NCT04987086Not ApplicableRecruiting
68Ga-PSMA PET in the Renal Cell Carcinoma
NCT07052214Phase 3Recruiting
PSMA PET Combined With MRI for the Detection of PCa
NCT05622162Phase 3Active Not Recruiting
Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7
Showing all 5 trials